Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,609 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (799)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML(MPDMDSBMT) | terminated | Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00062231 | Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer | terminated | N/A | 351 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK |
| 8 |
| Sep 24, 2012 |
| clinicaltrials |
| NCT00676728 | A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 10 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Sep 14, 2012 | clinicaltrials |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | terminated | N/A | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2012 | clinicaltrials |
| NCT00113321 | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00443300 | Effectiveness of Protected Environment Rooms for AML and MDS | terminated | — | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00513305 | Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia | terminated | Phase 3 | 67 | CephalonINDUSTRY | 2 | Aug 1, 2012 | clinicaltrials |
| NCT01645124 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)(CYTO-PV) | terminated | Phase 3 | 365 | Consorzio Mario Negri SudOTHER | 1 | Jul 20, 2012 | clinicaltrials |
| NCT00893997 | PR1 Vaccination in Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2012 | clinicaltrials |
| NCT00253552 | G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders | terminated | N/A | 4 | OHSU Knight Cancer InstituteOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00827099 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 5 | Northside Hospital, Inc.OTHER | 1 | Mar 23, 2012 | clinicaltrials |
| NCT01066468 | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 13, 2012 | clinicaltrials |
| NCT01546337 | Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome(EPO) | terminated | — | 30 | Rennes University HospitalOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00446303 | A Phase II Study of Maintenance With Azacitidine in MDS Patients | terminated | Phase 2 | 39 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00245128 | Imatinib Mesylate in Treating Patients With Myelofibrosis | terminated | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | terminated | Phase 2 | 50 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Dec 7, 2011 | clinicaltrials |
| NCT00519090 | Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENEST) | terminated | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 7, 2011 | clinicaltrials |
| NCT00430443 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | terminated | Phase 1 | 3 | Callisto PharmaceuticalsINDUSTRY | 1 | Aug 31, 2011 | clinicaltrials |
| NCT00915811 | Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin(FB-ATG) | terminated | Phase 2 | 20 | King's College Hospital NHS TrustOTHER | 1 | Aug 17, 2011 | clinicaltrials |
| NCT00839059 | Lenalidomide In Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 14 | University of UlmOTHER | 1 | Jul 29, 2011 | clinicaltrials |
| NCT00381693 | Azacitidine in Treating Patients With Myelofibrosis | terminated | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Apr 21, 2011 | clinicaltrials |
| NCT00531310 | Reduced Intensity AlloSCT in(CML) With Persistent Disease(CML) | terminated | Phase 2 | 5 | Columbia UniversityOTHER | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | terminated | Phase 1 | 100 | ExelixisINDUSTRY | 1 | Apr 5, 2011 | clinicaltrials |
| NCT00813501 | Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases | terminated | — | 60 | City of Hope Medical CenterOTHER | 1 | Mar 7, 2011 | clinicaltrials |
| NCT01034410 | A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 90 | Antisoma ResearchINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT00486265 | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 47 | AstraZenecaINDUSTRY | 2 | Dec 21, 2010 | clinicaltrials |
| NCT00279773 | Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 | 34 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 30, 2010 | clinicaltrials |
| NCT00322673 | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 14 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00004058 | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder | terminated | Phase 1 | — | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jan 26, 2010 | clinicaltrials |
| NCT00306332 | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 3 | 250 | Radboud University Medical CenterOTHER | 1 | Aug 18, 2009 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
| NCT00461929 | Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib(GIST) | terminated | Phase 4 | 68 | University Health Network, TorontoOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00363025 | A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. | terminated | Phase 3 | 465 | Acute Leukemia French AssociationOTHER | 1 | Feb 21, 2008 | clinicaltrials |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 50 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 17, 2008 | clinicaltrials |
| NCT00511121 | Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) | terminated | Phase 2 | 5 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00126893 | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | terminated | Phase 1 | 36 | Celgene CorporationINDUSTRY | 1 | May 15, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00219765 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients | terminated | Phase 1 / Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Nov 28, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Oct 10, 2012source: clinicaltrials